To assist us in evaluating the effectiveness of this activity, please complete the following pretest.

*1.Which of the following best describes your profession?(Required.)

MD/DO

NP

PA

RN

PharmD/RPh

Other (please specify)

*2.Which of the following best describes your specialty?(Required.)

Allergy

Pulmonology

Internal Medicine/Family Practice/General Practice

Other (please specify)

*3.How confident are you in the management of patients with moderate-to-severe asthma in your practice?(Required.)

Very confident

Confident

Neutral

Little confidence

No confidence

*4.Evelyn is a 48-year-old woman with uncontrolled asthma. Her current medications include medium-dose ICS-formoterol and SABA prn, which she reports adherence to.  She has had one exacerbation requiring hospital admission and a short course of OCS in the past year. She has comorbid CRSwNP and no other notable environmental factors. Biomarker testing reveals IgE = 60 kU/L, EOS = 450 cells/mL, FeNO = 50 ppb. Which of the following would you recommend for her?(Required.)

Step up to high-dose ICS-formoterol

Start Anti-IL-5

Start Anti-IL-4Ra

Start Anti-TSLP

*5.In a recent retrospective study of asthma patients, which of the following factors was found to be a characteristic of patients who required switching biologics? (Required.)

Higher blood eosinophil counts

Older age

Lower baseline pulmonary function indices

*6.Jeremy is a 30-year-old man with a history of uncontrolled asthma who began a trial of a biologic therapy 4 months ago. He reports decreased cough and shortness of breath but has recently had an exacerbation requiring a short course of OCS. Which of the following would you recommend?  (Required.)

Continue current biologic trial to assess response after 6-12 months of treatment

Switch to a different biologic

Discontinue the biologic

*7.How does current evidence from real-world studies compare with RCT data on the long-term efficacy of biologic therapies for moderate-to-severe asthma?(Required.)

Long-term efficacy is similarly sustained in both patient populations

Long-term efficacy is similarly reduced in both patient populations

Long-term efficacy is reduced in real-world vs clinical trial patient populations

*8.In long-term trials of both dupilumab (TRAVERSE) and mepolizumab (COLUMBA), improvements in exacerbations, asthma control, lung function, OCS use, and QOL were sustained with extended treatment up to how long? (Required.)

1 year

2 years

3 years

>3 years

*9.Please complete and submit this survey.(Required.)

Name:

Email: